Cellectis S.A (CLLS)

[Monksdream]

Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023. The additional investment will be made by way of subscription of 10,000,000 “class A” convertible preferred shares and 18,000,000 “class B” convertible preferred shares, in each case at a price of $5.00 per share (the “Additional Investment”).

[Money hunt]

Still on fire 🔥 Big deal in the works

[Money hunt]

Popping pills and buying shares and flying everywhere dudes !!!

[TheFinalCD]

2.99 on sale

[TheFinalCD]

i did just buy 2k @ 2.48 then it had a nice pop

more green is good

[TheFinalCD]

yeah they had me cough my shares back up, for a small profit

they=algos


first off they gapped it up way too high in the 1st place, so its hard to go in with size when the previous close was .97

they do this BS all the time to retail

when news hits you have no chance of buying in low, they rail it up so fast, before you even get done reading the news

then they short it back until it finds support or they decide to change directions

as a day trader Im so sick of this routine

[Jess070283]

Next stop $4+ IMO…

[MetaMonster]

Not with FDA green light

[zj3001]

The $80m upfront for 22% equity suggest the market cap should be about $363m + other assets.

[jchords]

Think it’ll be a while?

[MetaMonster]

Huge news CLLS Rnaz is next

[Monksdream]

Long day ahead

[TheFinalCD]

NICE NEWS

https://www.globenewswire.com/news-release/2023/11/01/2770788/0/en/Cellectis-Announces-Strategic-Collaboration-and-Investment-Agreements-with-AstraZeneca.html

https://dilutiontracker.com/app/search/CLLS

[Monksdream]

Will it grow legs after 9:30
Will it trend north for days, weeks, months

[tw0122]

straZeneca to Invest $245 Million in Deal With Cellectis

Source: Dow Jones News
By Ben Otto


British drugmaker AstraZeneca plans to invest $245 million in a deal with biotechnology company Cellectis to develop next-generation therapeutics in oncology, immunology and rare diseases.

AstraZeneca said Wednesday that it will initially make a $105 million payment to Paris-based Cellectis in the fourth quarter, comprising an $80 million equity investment, for a 22% stake in the company, and $25 million in cash.

AstraZeneca plans to make a further $140 million equity investment, subject to regulatory and other approvals, with a closing in early 2024, taking its total stake in Cellectis to 44%.

AstraZeneca said it plans to leverage Cellectis's gene-editing technologies and manufacturing capabilities to design novel cell and gene therapy products.

Cellectis will be eligible to receive an investigational new drug option fee and various milestone payments ranging from $70 million to up to $220 million for each of 10 candidate products, plus tiered royalties, AstraZeneca said.

AstraZeneca will retain an option for an exclusive license for the products developed under the research collaboration agreement.

[Monksdream]

CLLS under $2

[Monksdream]

Cellectis SA NASDAQ: CLLS

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

[Frankestin]

https://www.cellectis.com/uploads/files/051123_PosterASGCT2023_BAOa.pdf
https://www.cellectis.com/uploads/files/UCART123_AMELI-01_Phase_1_Oral_Presentation_ASGCT_2023_Final_Upload.pdf

[Frankestin]

file:///C:/Users/bozh/Downloads/UCART123_AMELI-01_Phase_1_Oral_Presentation_ASGCT_2023_Final_Upload.pdf
file:///C:/Users/bozh/Downloads/051123_PosterASGCT2023_BAOa.pdf

Evidence of UCART123 anti-tumor activity was observed in four patients out of fifteen at DL2 or above with best overall responses in the FCA arm. Two out of eight patients (25%) at DL2 in the FCA arm achieved meaningful response: * A patient who failed five prior lines of therapy experienced a durable minimal residual disease (MRD) negative complete response (CR) with full count recovery at Day 56 that continues beyond one year.

* A patient with stable disease achieved greater than 90% bone marrow blast reduction (60% to 5%) at Day 28.

The preliminary data show that adding alemtuzumab to the FC LD regimen was associated with sustained lymphodepletion and significantly higher UCART123 cell expansion, which correlated with improved anti-tumor activity.

Patient Enrollment in a 2-Dose Regimen Arm

Overall, these preliminary data support the continued administration of UCART123 after FCA lymphodepletion in patients with r/r AML. Based on observed UCART123 expansion patterns and cytokine profiles, pursuant to an amended protocol, a second dose of UCART123 is given after 10-14 days to allow for additional UCART123 expansion and clinical activity without the use of additional lymphodepletion. The UCART123 cell expansion from the second dose of UCART123, in the setting of reduced disease burden, is expected to be safe and allow for clearance of residual disease.

“These clinically meaningful preliminary data from the AMELI-01 study are very encouraging for patients and for the future of allogeneic CART-cell therapy. AML is a disease with an urgent need for alternative treatment options for patients, and we are excited to be moving the study forward,” said Dr. Mark Frattini, M.D., Ph.D., Chief Medical Officer at Cellectis. “We have now implemented a two-dose regimen arm for our AMELI-01 trial and we look forward to sharing future updates as they become available.”

[Frankestin]

grabbed a handful yesterday.
I wonder if tomorrow they surprise us a little?

[Frankestin]

https://ih.advfn.com/stock-market/NASDAQ/cellectis-CLLS/stock-news/83912184/cellectis-announces-withdrawal-of-follow-on-offeri
Seems like it's better now...
I hope they sell them to pfizer

[Frankestin]

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

* UCART22: ANTI-TUMOR ACTIVITY OBSERVED IN 60% (N=3) OF PATIENTS AT DL3 USING FCA LYMPHODEPLETION
* AMELI-01 STUDY (EVALUATING UCART123) NOW ENROLLING PATIENTS IN A TWO-DOSE REGIMEN ARM AT DL2
* UCART123: 25% (N=2) OF PATIENTS AT DL2 IN FCA ARM ACHIEVED MEANINGFUL RESPONSE
* NEXT DATA SET IS EXPECTED TO BE RELEASED IN 2023
* UCART123: ONE PATIENT EXPERIENCED A DURABLE MINIMAL RESIDUAL DISEASE (MRD)-NEGATIVE COMPLETE RESPONSE THAT CONTINUES BEYOND 12 MONTHS


dry hands still sell

[Frankestin]

will there be something interesting?

November 4(th), 2022, at 8:00 AM EDT / 2:00 PM CET. The call will include the Company’s third quarter results and an update on business activities.

he is quite slapped in the face and someone sees him for $ 2

in a while they will have to load money somehow ...
apparently they refused to bid when she was high

[Frankestin]

also interesting here!
Yes, yes

[whytestocks]

News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates

Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline Manufacturing to take place at Lonza’s GMP site in Geleen, Netherlands Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS), a cl...

Read the whole news CLLS - Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates

[n4807g]

J.P Morgan Healthcare conference presentation is worth listening to. At current valuation CLLS is undervalued.....very undervalued.

[n4807g]

Not uncommon with new therapies. Much too early to draw any conclusions about UCART123. The trial will most likely resume with recommended adjustments.

[Avispa]

https://seekingalpha.com/news/3293436-cellectis-29-percent-premarket-fda-hold-studies-ucart123-fatality

[north40000]

FDA imposes clinical hold on CART-123.... patient death.

[n4807g]

with the GILD acquisition of KITE the potential for CAR-T, and more specifically Alogeneic CAR-T increases dramatically. FWIW CLLS is one of the leaders (if not the leader) in this sphere. Additionally, their partnership with Pfizer opens tantalizing possibilities for the future if the technology, and their therapies prove valid.

Something worth reading:

http://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_cellectis_enter_into_global_strategic_cancer_immunotherapy_collaboration

and of particular interest.....

Under the terms of the agreement, Pfizer has exclusive rights to pursue development and commercialization of CAR-T therapies, in the field of oncology, directed at a total of fifteen targets selected by Pfizer. Both companies will work together on preclinical research and Pfizer will be responsible for the development and potential commercialization of any CAR-T therapies for the Pfizer-selected targets. In addition, the agreement provides for a total of twelve targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets and Cellectis will work independently on eight additional targets. Cellectis will be responsible for clinical development and commercialization of CAR-T therapeutics for the Cellectis-selected targets. Pfizer has right of first refusal to the four Cellectis-selected targets.

I am long CLLS and accumulating shares.

[u508]

Cellectis’CAR-T cells act as “universal donor” cells.

Other CAR-T therapies must remove immune system cells from a patient’s blood. Then these cells have to be worked on in a lab. They must be multiplied. Genes must be edited. Then the cells have to be reinfused into the patient to do their work.

Each patient is a one-off therapeutic product! Each dose will cost tens of thousands of dollars just to make.

Cellectis, however, has created a line of CAR-T cells that can work in anyone.

[Sixman]

I read that too. The CART Space is interesting and I understand CLLS is developing a method that would allow more treatment of multiple types of cancer?

It's showing good signs of strength.

[u508]

interest due to successful treatment of little girl using their "universal" CAR-T cells. Wish I had cash to buy more shares but I'm a small investor - $20+ is expensive for me....

[Sixman]

Lots of interest last few days. Anyone out there following CLLS?

[lucmariepierre]

Sincerely i have no idea
It was 45 dollars
Now it is 20 dollars

This stock is unbalanced i think

Why so high or so low ?

[murocman]

Anyone have any idea on when the first results from the Ph I trial at UCL might be published. All I can find is the the trial is open label and is non-comparative---no information on number of patients or time to completion.

GLTA,

Murocman

[biscotte]

CNBC : CLLS ==> 100$ ! ???

[north40000]

http://in.reuters.com/article/us-health-celltherapy-idINKCN0XX1F7?feedType=RSS&feedName=health&utm_source=Twitter&utm_medium=Social&utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29

"A second baby with aggressive leukaemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, remains in remission, the French biotech firm said.

Cellectis shares jumped 14 percent following Friday's news.

The first human use of the company's cell therapy made headlines worldwide in November when one-year-old Layla was cleared of previously incurable leukaemia at Britain's Great Ormond Street Hospital (GOSH).

Details of the latest compassionate care case, also treated at GOSH, were presented at the American Society of Gene & Cell Therapy annual meeting in Washington.

The so-called UCART19 injection works by adding new genes to healthy donated immune cells known as T-cells, which arm them against leukaemia.[more]

[venturecapp]

Post-Holiday Action: Movers and Shakers in Biotech - article mentions Cellectis

http://marketexclusive.com/post-holiday-action-movers-and-shakers-in-biotech/1207/

[MrPoppaGeorgeo]

Et like da (I) not da (o)(o)

[~Angel~]

vroom

[MrPoppaGeorgeo]

CLLS has the V power (I)

[MrPoppaGeorgeo]

Boooom CLLS was just at $24

[cantgetmyname]

http://www.reuters.com/article/2015/11/05/us-health-leukaemia-cellectis-idUSKCN0SU2PO20151105

[MrPoppaGeorgeo]

Nice, this moves along with JUNO..it's should be back in the 40's soon

[Don'tDrinkTheKoolAid]

I just go in this 37 it's a volatility squeeze look at the Bollinger bands. Where do you see this headed? Volume is picking up to.

[MrPoppaGeorgeo]

CLLS news http://ih.advfn.com/p.php?pid=nmona&article=67231007

[MrPoppaGeorgeo]

Ready for a reload

[MrPoppaGeorgeo]

CLLS newsssss

[~Angel~]

and Poppa is nice, Liam ~ hehe

Very nice poppa!!